Compare Invesco DB Agriculture Fund (DBA) vs McKesson Corporation (MCK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Invesco DB Agriculture Fund vs McKesson Corporation — how do they compare? Invesco DB Agriculture Fund trades at $27.59, while McKesson Corporation trades at $899.06 (market cap $102.58B). The key difference: McKesson Corporation pays a 0.43% dividend while Invesco DB Agriculture Fund pays none. Which is the better fit depends on your goals.
| DBA | MCK | |
|---|---|---|
52-Week High | $28.73 | $995.69 |
52-Week Low | $25.44 | $659.01 |
Market Cap | — | $102.58B |
Sector | — | Health |
Enterprise Value | — | $109.12B |
Dividend Yield | — | 0.43% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DBA, the Invesco DB Agriculture Fund ETF, trades at $27.62, up 0.69% today, and has shown strong performance with a 5% gain over the past month, outperforming the S&P 500. The technical outlook is bullish based on moving averages, while oscillators are neutral. Recent news highlights agricultural commodity strength, with DBA consolidating near highs amid a bullish trend since 2020, supported by a 3.25% yield and diversified futures exposure.
The outlook for DBA remains positive due to favorable agricultural market conditions and geopolitical factors driving commodity prices. Key risks include sector volatility and management fees. Analyst sentiment is constructive, viewing the ETF as a play on rising agricultural demand, though investors should monitor commodity price fluctuations and global supply chain disruptions.
McKesson (MCK) trades at $869.58, down 0.14% on the day, with a bullish technical signal supported by moving averages. The stock shows strong fundamentals with revenue growth to $359.05B in 2025 and consistent earnings beats, including Q2 2026 EPS of $9.93 versus $9.56 expected. Valuation metrics like P/E of 23.33 and P/S of 0.26 indicate reasonable pricing relative to peers. Recent news highlights Q1 2027 results exceeding expectations and raised full-year guidance, driven by specialty drug and oncology growth.
Outlook remains positive with 80% analyst buy ratings and a $1,000 consensus price target, suggesting 15% upside. Risks include thin net margins of 1.12% and high liabilities at $76.83B, which could pressure equity during economic downturns. Investors should focus on execution of raised guidance and margin improvements from cost efficiencies.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Invesco DB Agriculture Fund
The index, which is comprised of one or more underlying commodities ("index commodities"), is intended to reflect the agricultural sector. The fund pursues its investment objective by investing in a portfolio of exchange-traded futures.
Read more on DBA →About McKesson Corporation
McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →
